S-1/A Filing

CDT EQUITY INC. CIK: 1896212

Filing Information

Form Type	S-1/A
Accession Number	`0001493152-23-043429`
Period End Date	20230930
Filing Date	20231201
Fiscal Year	N/A
Fiscal Period	N/A
XBRL Instance	forms-1a_htm.xml

Filing Contents

This filing contains the following financial statements:

Balance Sheet 91 Income Statement 88 Cash Flow Statement 161 Stockholders Equity 69

Balance Sheet 91 line items

Line Item	Tag	Value	Unit	Period
Common stock, par value	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Common stock, par value	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Common stock, par value	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Common stock, shares authorized	`CommonStockSharesAuthorized`	400.00M	shares	Point-in-time
Common stock, shares authorized	`CommonStockSharesAuthorized`	400.00M	shares	Point-in-time
Common stock, shares authorized	`CommonStockSharesAuthorized`	250.00M	shares	Point-in-time
Common stock, shares issued	`CommonStockSharesIssued`	2,000.00	shares	Point-in-time
Common stock, shares issued	`CommonStockSharesIssued`	1,000.00	shares	Point-in-time
Common stock, shares outstanding	`CommonStockSharesOutstanding`	2,000.00	shares	Point-in-time
Common stock, shares outstanding	`CommonStockSharesOutstanding`	1,000.00	shares	Point-in-time
Preferred stock, par value	`PreferredStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$8.64M	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	-	USD	Point-in-time
Preferred stock, par value	`PreferredStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Preferred stock, shares authorized	`PreferredStockSharesAuthorized`	1.00M	shares	Point-in-time
Preferred stock, shares authorized	`PreferredStockSharesAuthorized`	-	shares	Point-in-time
Prepaid expenses and other current assets	`PrepaidExpenseAndOtherAssetsCurrent`	$1.80M	USD	Point-in-time
Preferred stock, shares issued	`PreferredStockSharesIssued`	-	shares	Point-in-time
Preferred stock, shares issued	`PreferredStockSharesIssued`	-	shares	Point-in-time
Prepaid expenses and other current assets	`PrepaidExpenseAndOtherAssetsCurrent`	-	USD	Point-in-time
Preferred stock, shares outstanding	`PreferredStockSharesOutstanding`	-	shares	Point-in-time
Total current assets	`AssetsCurrent`	$10.44M	USD	Point-in-time
Total current assets	`AssetsCurrent`	-	USD	Point-in-time
Preferred stock, shares outstanding	`PreferredStockSharesOutstanding`	-	shares	Point-in-time
Intangible assets - research and development	`IntangibleAssetsNetExcludingGoodwill`	-	USD	Point-in-time
Intangible assets - research and development	`IntangibleAssetsNetExcludingGoodwill`	$5.00K	USD	Point-in-time
Intangible assets - research and development	`IntangibleAssetsNetExcludingGoodwill`	$5.00K	USD	Point-in-time
Deposits and other long-term assets	`DepositsAndOtherAssetsNoncurrent`	$1.57M	USD	Point-in-time
Deposits and other long-term assets	`DepositsAndOtherAssetsNoncurrent`	-	USD	Point-in-time
Total Assets	`Assets`	$5.00K	USD	Point-in-time
Total Assets	`Assets`	$12.02M	USD	Point-in-time
Total Assets	`Assets`	-	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$35.00K	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	-	USD	Point-in-time
Accrued expenses and other current liabilities	`AccruedExpensesAndOtherLiabilitiesCurrent`	-	USD	Point-in-time
Accrued expenses and other current liabilities	`AccruedExpensesAndOtherLiabilitiesCurrent`	$1.20M	USD	Point-in-time
Income taxes payable	`AccruedIncomeTaxesCurrent`	-	USD	Point-in-time
Income taxes payable	`AccruedIncomeTaxesCurrent`	-	USD	Point-in-time
Accrued professional fees	`AccruedProfessionalFeesCurrent`	$1.61M	USD	Point-in-time
Accrued professional fees	`AccruedProfessionalFeesCurrent`	$2.25M	USD	Point-in-time
Accrued professional fees	`AccruedProfessionalFeesCurrent`	$1.31M	USD	Point-in-time
Accrued payroll and other current liabilities	`EmployeeRelatedLiabilitiesCurrent`	$33.00K	USD	Point-in-time
Accrued payroll and other current liabilities	`EmployeeRelatedLiabilitiesCurrent`	$927.00K	USD	Point-in-time
Accrued payroll and other current liabilities	`EmployeeRelatedLiabilitiesCurrent`	$338.00K	USD	Point-in-time
Option liability	`OptionLiabilityCurrent`	$742.00K	USD	Point-in-time
Option liability	`OptionLiabilityCurrent`	-	USD	Point-in-time
Convertible promissory note payable	`ConvertiblePromissoryNotePayable`	$804.00K	USD	Point-in-time
Convertible promissory note payable	`ConvertiblePromissoryNotePayable`	-	USD	Point-in-time
Note payable - Sponsor	`NotesPayableCurrent`	-	USD	Point-in-time
Note payable - Sponsor	`NotesPayableCurrent`	$177.00K	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$2.58M	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$4.60M	USD	Point-in-time
Convertible notes payable, carried at fair value	`ConvertibleLongTermNotesPayable`	$1.83M	USD	Point-in-time
Convertible notes payable, carried at fair value	`ConvertibleLongTermNotesPayable`	-	USD	Point-in-time
Convertible notes payable, carried at fair value	`ConvertibleLongTermNotesPayable`	$749.00K	USD	Point-in-time
Deferred revenue	`DeferredRevenueNoncurrent`	$2.67M	USD	Point-in-time
Deferred revenue	`DeferredRevenueNoncurrent`	$4.08M	USD	Point-in-time
Deferred revenue	`DeferredRevenueNoncurrent`	$2.96M	USD	Point-in-time
Notes payable	`NotesPayableNoncurrent`	-	USD	Point-in-time
Notes payable	`NotesPayableNoncurrent`	-	USD	Point-in-time
Notes payable	`NotesPayableNoncurrent`	$175.00K	USD	Point-in-time
Option liability	`OptionLiabilityNonCurrent`	$1.42M	USD	Point-in-time
Option liability	`OptionLiabilityNonCurrent`	-	USD	Point-in-time
Derivative warrant liability	`SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares`	-	USD	Point-in-time
Derivative warrant liability	`SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares`	$92.00K	USD	Point-in-time
Deferred commission payable	`DeferredCommissionPayableNonCurrent`	-	USD	Point-in-time
Deferred commission payable	`DeferredCommissionPayableNonCurrent`	$5.74M	USD	Point-in-time
Total Liabilities	`Liabilities`	$13.10M	USD	Point-in-time
Total Liabilities	`Liabilities`	$10.09M	USD	Point-in-time
Commitments and Contingencies (Note 6)	`CommitmentsAndContingencies`	-	USD	Point-in-time
Commitments and Contingencies (Note 6)	`CommitmentsAndContingencies`	-	USD	Point-in-time
Commitments and Contingencies (Note 6)	`CommitmentsAndContingencies`	-	USD	Point-in-time
Common stock value	`CommonStockValue`	-	USD	Point-in-time
Common stock value	`CommonStockValue`	-	USD	Point-in-time
Preferred stock, $0.0001 par value; 1,000,000 shares authorized; none issued and outstanding	`PreferredStockValue`	-	USD	Point-in-time
Preferred stock, $0.0001 par value; 1,000,000 shares authorized; none issued and outstanding	`PreferredStockValue`	-	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-5.88M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-13.10M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-10.76M	USD	Point-in-time
Accumulated other comprehensive loss	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$639.00K	USD	Point-in-time
Accumulated other comprehensive loss	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$675.00K	USD	Point-in-time
Total Stockholders Equity (Deficit)	`StockholdersEquity`	$-6.14M	USD	Point-in-time
Total Stockholders Equity (Deficit)	`StockholdersEquity`	$-6.49M	USD	Point-in-time
Total Stockholders Equity (Deficit)	`StockholdersEquity`	$-10.09M	USD	Point-in-time
Total Stockholders Equity (Deficit)	`StockholdersEquity`	$-2.36M	USD	Point-in-time
Total Stockholders Equity (Deficit)	`StockholdersEquity`	$-1.08M	USD	Point-in-time
Total Stockholders Equity (Deficit)	`StockholdersEquity`	$-15.04M	USD	Point-in-time
Total Stockholders Equity (Deficit)	`StockholdersEquity`	$-5.94M	USD	Point-in-time
Total Liabilities and Stockholders Equity (Deficit)	`LiabilitiesAndStockholdersEquity`	-	USD	Point-in-time
Total Liabilities and Stockholders Equity (Deficit)	`LiabilitiesAndStockholdersEquity`	$12.02M	USD	Point-in-time
Total Liabilities and Stockholders Equity (Deficit)	`LiabilitiesAndStockholdersEquity`	$5.00K	USD	Point-in-time

Income Statement 88 line items

Line Item	Tag	Value	Unit	Period
Research and development expenses	`ResearchAndDevelopmentExpense`	$38.00K	USD	3 Qtrs
Research and development expenses	`ResearchAndDevelopmentExpense`	$28.00K	USD	Annual
Research and development expenses	`ResearchAndDevelopmentExpense`	$37.00K	USD	Annual
Research and development expenses	`ResearchAndDevelopmentExpense`	-	USD	3 Qtrs
Research and development expenses	`ResearchAndDevelopmentExpense`	$38.00K	USD	1 Quarter
Research and development expenses	`ResearchAndDevelopmentExpense`	-	USD	1 Quarter
General and administrative expenses	`GeneralAndAdministrativeExpense`	$1.33M	USD	3 Qtrs
General and administrative expenses	`GeneralAndAdministrativeExpense`	$3.05M	USD	Annual
General and administrative expenses	`GeneralAndAdministrativeExpense`	$2.89M	USD	Annual
General and administrative expenses	`GeneralAndAdministrativeExpense`	$775.00K	USD	1 Quarter
General and administrative expenses	`GeneralAndAdministrativeExpense`	$1.07M	USD	1 Quarter
General and administrative expenses	`GeneralAndAdministrativeExpense`	$4.37M	USD	3 Qtrs
Funding expenses	`FundingExpenses`	$120.00K	USD	1 Quarter
Funding expenses	`FundingExpenses`	$74.00K	USD	Annual
Funding expenses	`FundingExpenses`	$255.00K	USD	Annual
Funding expenses	`FundingExpenses`	-	USD	1 Quarter
Funding expenses	`FundingExpenses`	-	USD	3 Qtrs
Funding expenses	`FundingExpenses`	$120.00K	USD	3 Qtrs
Total expenses	`OperatingExpenses`	$3.16M	USD	Annual
Total expenses	`OperatingExpenses`	$4.37M	USD	3 Qtrs
Total expenses	`OperatingExpenses`	$1.49M	USD	3 Qtrs
Total expenses	`OperatingExpenses`	$3.17M	USD	Annual
Total expenses	`OperatingExpenses`	$933.00K	USD	1 Quarter
Total expenses	`OperatingExpenses`	$1.07M	USD	1 Quarter
Loss from operation	`OperatingIncomeLoss`	$-4.37M	USD	3 Qtrs
Loss from operation	`OperatingIncomeLoss`	$-1.49M	USD	3 Qtrs
Loss from operation	`OperatingIncomeLoss`	$-3.17M	USD	Annual
Loss from operation	`OperatingIncomeLoss`	$-1.07M	USD	1 Quarter
Loss from operation	`OperatingIncomeLoss`	$-3.16M	USD	Annual
Loss from operation	`OperatingIncomeLoss`	$-933.00K	USD	1 Quarter
Other expense	`OtherNonoperatingIncomeExpense`	$-330.00K	USD	3 Qtrs
Other expense	`OtherNonoperatingIncomeExpense`	$-484.00K	USD	Annual
Other expense	`OtherNonoperatingIncomeExpense`	$-23.00K	USD	1 Quarter
Other expense	`OtherNonoperatingIncomeExpense`	$2.15M	USD	3 Qtrs
Other expense	`OtherNonoperatingIncomeExpense`	$-1.73M	USD	Annual
Other expense	`OtherNonoperatingIncomeExpense`	$3.10M	USD	1 Quarter
Interest expense, net	`InterestIncomeExpenseNonoperatingNet`	-	USD	3 Qtrs
Interest expense, net	`InterestIncomeExpenseNonoperatingNet`	$-92.00K	USD	3 Qtrs
Interest expense, net	`InterestIncomeExpenseNonoperatingNet`	$-47.00K	USD	1 Quarter
Interest expense, net	`InterestIncomeExpenseNonoperatingNet`	-	USD	1 Quarter
Total other income	`NonoperatingIncomeExpense`	$3.06M	USD	1 Quarter
Total other income	`NonoperatingIncomeExpense`	$-484.00K	USD	Annual
Total other income	`NonoperatingIncomeExpense`	$-330.00K	USD	3 Qtrs
Total other income	`NonoperatingIncomeExpense`	$2.05M	USD	3 Qtrs
Total other income	`NonoperatingIncomeExpense`	$-1.73M	USD	Annual
Total other income	`NonoperatingIncomeExpense`	$-23.00K	USD	1 Quarter
Net income (loss)	`NetIncomeLoss`	$-1.82M	USD	3 Qtrs
Net income (loss)	`NetIncomeLoss`	$-4.89M	USD	Annual
Net income (loss)	`NetIncomeLoss`	$-956.00K	USD	1 Quarter
Net income (loss)	`NetIncomeLoss`	$-3.66M	USD	Annual
Net income (loss)	`NetIncomeLoss`	$1.99M	USD	1 Quarter
Net income (loss)	`NetIncomeLoss`	$-2.31M	USD	3 Qtrs
Earnings per share, basic	`EarningsPerShareBasic`	$-0.03	USD	1 Quarter
Earnings per share, basic	`EarningsPerShareBasic`	$-2.44K	USD	Annual
Earnings per share, basic	`EarningsPerShareBasic`	$-0.04	USD	3 Qtrs
Earnings per share, basic	`EarningsPerShareBasic`	$0.03	USD	1 Quarter
Earnings per share, basic	`EarningsPerShareBasic`	$-3.66K	USD	Annual
Earnings per share, basic	`EarningsPerShareBasic`	$-0.06	USD	3 Qtrs
Earnings per share, diluted	`EarningsPerShareDiluted`	$-0.06	USD	3 Qtrs
Earnings per share, diluted	`EarningsPerShareDiluted`	$-2.44K	USD	Annual
Earnings per share, diluted	`EarningsPerShareDiluted`	$-0.03	USD	1 Quarter
Earnings per share, diluted	`EarningsPerShareDiluted`	-	USD	1 Quarter
Earnings per share, diluted	`EarningsPerShareDiluted`	$-3.66K	USD	Annual
Earnings per share, diluted	`EarningsPerShareDiluted`	$-0.07	USD	3 Qtrs
Weighted average number of shares outstanding, basic	`WeightedAverageNumberOfSharesOutstandingBasic`	32.31M	shares	1 Quarter
Weighted average number of shares outstanding, basic	`WeightedAverageNumberOfSharesOutstandingBasic`	32.31M	shares	3 Qtrs
Weighted average number of shares outstanding, basic	`WeightedAverageNumberOfSharesOutstandingBasic`	1,000.00	shares	Annual
Weighted average number of shares outstanding, basic	`WeightedAverageNumberOfSharesOutstandingBasic`	65.41M	shares	1 Quarter
Weighted average number of shares outstanding, basic	`WeightedAverageNumberOfSharesOutstandingBasic`	2,000.00	shares	Annual
Weighted average number of shares outstanding, basic	`WeightedAverageNumberOfSharesOutstandingBasic`	64.89M	shares	3 Qtrs
Weighted average number of shares outstanding, diluted	`WeightedAverageNumberOfDilutedSharesOutstanding`	1,000.00	shares	Annual
Weighted average number of shares outstanding, diluted	`WeightedAverageNumberOfDilutedSharesOutstanding`	32.31M	shares	1 Quarter
Weighted average number of shares outstanding, diluted	`WeightedAverageNumberOfDilutedSharesOutstanding`	66.13M	shares	1 Quarter
Weighted average number of shares outstanding, diluted	`WeightedAverageNumberOfDilutedSharesOutstanding`	65.49M	shares	3 Qtrs
Weighted average number of shares outstanding, diluted	`WeightedAverageNumberOfDilutedSharesOutstanding`	32.31M	shares	3 Qtrs
Weighted average number of shares outstanding, diluted	`WeightedAverageNumberOfDilutedSharesOutstanding`	2,000.00	shares	Annual
Foreign currency translation adjustment	`OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent`	$36.00K	USD	3 Qtrs
Foreign currency translation adjustment	`OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent`	$79.00K	USD	Annual
Foreign currency translation adjustment	`OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent`	$608.00K	USD	1 Quarter
Foreign currency translation adjustment	`OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent`	$753.00K	USD	Annual
Foreign currency translation adjustment	`OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent`	$610.00K	USD	1 Quarter
Foreign currency translation adjustment	`OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent`	$1.27M	USD	3 Qtrs
Total comprehensive loss	`ComprehensiveIncomeNetOfTax`	$-2.28M	USD	3 Qtrs
Total comprehensive loss	`ComprehensiveIncomeNetOfTax`	$-547.00K	USD	3 Qtrs
Total comprehensive loss	`ComprehensiveIncomeNetOfTax`	$-348.00K	USD	1 Quarter
Total comprehensive loss	`ComprehensiveIncomeNetOfTax`	$-4.13M	USD	Annual
Total comprehensive loss	`ComprehensiveIncomeNetOfTax`	$-3.58M	USD	Annual
Total comprehensive loss	`ComprehensiveIncomeNetOfTax`	$2.60M	USD	1 Quarter

Cash Flow Statement 161 line items

Line Item	Tag	Value	Unit	Period
Net income (loss)	`NetIncomeLoss`	$-4.89M	USD	Annual
Net income (loss)	`NetIncomeLoss`	$-956.00K	USD	1 Quarter
Net income (loss)	`NetIncomeLoss`	$-3.66M	USD	Annual
Net income (loss)	`NetIncomeLoss`	$1.99M	USD	1 Quarter
Net income (loss)	`NetIncomeLoss`	$-2.31M	USD	3 Qtrs
Net income (loss)	`NetIncomeLoss`	$-1.82M	USD	3 Qtrs
Loss on option	`GainLossOnOption`	$1.30M	USD	Annual
Loss on sale of equity securities	`LossOnEquitySecuritiesReceivable`	$129.00K	USD	Annual
Loss on sale of equity securities	`LossOnEquitySecuritiesReceivable`	$76.00K	USD	Annual
Change in fair value of convertible notes payable	`ChangeInFairValueOfConvertibleNotesPayable`	$73.00K	USD	Annual
Change in fair value of convertible notes payable	`ChangeInFairValueOfConvertibleNotesPayable`	$265.00K	USD	Annual
Change in loan allowance	`ChangeInLoanAllowance`	-	USD	Annual
Change in loan allowance	`ChangeInLoanAllowance`	$331.00K	USD	Annual
Gain on investment in equity securities	`GainLossOnInvestments`	$34.00K	USD	3 Qtrs
Gain on investment in equity securities	`GainLossOnInvestments`	-	USD	3 Qtrs
(Gain) loss on change in fair value of Cizzle option	`GainLossOnChangeInFairValueOfCizzleOption`	$1.31M	USD	3 Qtrs
(Gain) loss on change in fair value of Cizzle option	`GainLossOnChangeInFairValueOfCizzleOption`	$-216.00K	USD	3 Qtrs
Gain on change in fair value of Vela option	`GainOnChangeInFairValueOfVelaOption`	-	USD	3 Qtrs
Gain on change in fair value of Vela option	`GainOnChangeInFairValueOfVelaOption`	$748.00K	USD	3 Qtrs
Loss on issuance of Vela option	`LossOnIssuanceOfVelaOption`	$1.01M	USD	3 Qtrs
Loss on issuance of Vela option	`LossOnIssuanceOfVelaOption`	-	USD	3 Qtrs
Unrealized foreign exchange loss	`ForeignCurrencyTransactionGainLossUnrealizedAfterTax`	-	USD	3 Qtrs
Unrealized foreign exchange loss	`ForeignCurrencyTransactionGainLossUnrealizedAfterTax`	$-4.00K	USD	3 Qtrs
Change in reserve for related party uncollectible loan	`ForeignCurrencyTransactionGainLossUnrealized`	$240.00K	USD	3 Qtrs
Change in reserve for related party uncollectible loan	`ForeignCurrencyTransactionGainLossUnrealized`	$118.00K	USD	1 Quarter
Change in reserve for related party uncollectible loan	`ForeignCurrencyTransactionGainLossUnrealized`	$118.00K	USD	1 Quarter
Change in reserve for related party uncollectible loan	`ForeignCurrencyTransactionGainLossUnrealized`	-	USD	3 Qtrs
Loss on related party loan forgiveness	`LossOnRelatedPartyLoanForgiveness`	-	USD	3 Qtrs
Loss on related party loan forgiveness	`LossOnRelatedPartyLoanForgiveness`	$12.00K	USD	3 Qtrs
Loss on change in fair value of convertible notes payable	`LossOnChangeInFairValueOfConvertibleNotesPayable`	$148.00K	USD	3 Qtrs
Loss on change in fair value of convertible notes payable	`LossOnChangeInFairValueOfConvertibleNotesPayable`	$423.00K	USD	3 Qtrs
Non-cash reduction of deferred income upon exercise of option liability	`NoncashReductionOfDeferredIncomeUponExerciseOfOptionLiability`	-	USD	3 Qtrs
Non-cash reduction of deferred income upon exercise of option liability	`NoncashReductionOfDeferredIncomeUponExerciseOfOptionLiability`	$1.48M	USD	3 Qtrs
Interest expense on convertible promissory note	`InterestExpenseOnConvertiblePromissoryNotePayable`	$86.00K	USD	3 Qtrs
Interest expense on convertible promissory note	`InterestExpenseOnConvertiblePromissoryNotePayable`	-	USD	3 Qtrs
Gain on warrant remeasurement	`GainOnWarrantRemeasurement`	-	USD	3 Qtrs
Gain on warrant remeasurement	`GainOnWarrantRemeasurement`	$131.00K	USD	3 Qtrs
Stock-based compensation expense	`ShareBasedCompensation`	$10.00K	USD	3 Qtrs
Stock-based compensation expense	`ShareBasedCompensation`	-	USD	3 Qtrs
Non-cash interest expense	`NoncashInterestExpense`	-	USD	3 Qtrs
Non-cash interest expense	`NoncashInterestExpense`	$8.00K	USD	3 Qtrs
Amortization of financed Directors and Officers insurance	`AdjustmentForAmortization`	$44.00K	USD	3 Qtrs
Amortization of financed Directors and Officers insurance	`AdjustmentForAmortization`	-	USD	3 Qtrs
Prepaid expenses and other current assets	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$-93.00K	USD	3 Qtrs
Prepaid expenses and other current assets	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	-	USD	3 Qtrs
Accounts payable	`IncreaseDecreaseInAccountsPayable`	-	USD	3 Qtrs
Accounts payable	`IncreaseDecreaseInAccountsPayable`	$6.00K	USD	3 Qtrs
Accrued expenses and other current liabilities	`IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities`	$-601.00K	USD	Annual
Accrued expenses and other current liabilities	`IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities`	$-105.00K	USD	3 Qtrs
Accrued expenses and other current liabilities	`IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities`	$-1.60M	USD	3 Qtrs
Accrued expenses and other current liabilities	`IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities`	$-1.36M	USD	Annual
Intangible assets	`IncreaseDecreaseInIntangibleAssetsCurrent`	$5.00K	USD	Annual
Intangible assets	`IncreaseDecreaseInIntangibleAssetsCurrent`	$5.00K	USD	3 Qtrs
Intangible assets	`IncreaseDecreaseInIntangibleAssetsCurrent`	-	USD	Annual
Intangible assets	`IncreaseDecreaseInIntangibleAssetsCurrent`	-	USD	3 Qtrs
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-1.39M	USD	3 Qtrs
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-2.92M	USD	3 Qtrs
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-2.15M	USD	Annual
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-2.27M	USD	Annual
Proceeds from issuance of option	`ProceedsFromIssuanceOfOption`	-	USD	Annual
Proceeds from issuance of option	`ProceedsFromIssuanceOfOption`	$148.00K	USD	Annual
Loans to related party	`PaymentsToFundLongtermLoansToRelatedParties`	$331.00K	USD	Annual
Loans to related party	`PaymentsToFundLongtermLoansToRelatedParties`	$357.00K	USD	3 Qtrs
Loans to related party	`PaymentsToFundLongtermLoansToRelatedParties`	$129.00K	USD	3 Qtrs
Loans to related party	`PaymentsToFundLongtermLoansToRelatedParties`	-	USD	Annual
Proceeds from loan repayment - related party	`ProceedsFromLoanRepaymentRelatedParty`	-	USD	3 Qtrs
Proceeds from loan repayment - related party	`ProceedsFromLoanRepaymentRelatedParty`	$585.00K	USD	3 Qtrs
Net cash used in investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-129.00K	USD	3 Qtrs
Net cash used in investing activities	`NetCashProvidedByUsedInInvestingActivities`	$228.00K	USD	3 Qtrs
Net cash used in investing activities	`NetCashProvidedByUsedInInvestingActivities`	-	USD	Annual
Net cash used in investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-183.00K	USD	Annual
Proceeds from Merger and related PIPE Financing, net of transaction costs	`ProceedsFromMergerAndRelatedPipeFinancingNetOfTransactionCosts`	-	USD	3 Qtrs
Proceeds from Merger and related PIPE Financing, net of transaction costs	`ProceedsFromMergerAndRelatedPipeFinancingNetOfTransactionCosts`	$8.49M	USD	3 Qtrs
Issuance of convertible notes payable	`IssuanceOfConvertibleNotesPayable`	$688.00K	USD	Annual
Issuance of convertible notes payable	`IssuanceOfConvertibleNotesPayable`	$928.00K	USD	Annual
Proceeds from note payable - Sponsor	`ProceedsFromRelatedPartyDebt`	$179.00K	USD	Annual
Proceeds from note payable - Sponsor	`ProceedsFromRelatedPartyDebt`	-	USD	3 Qtrs
Proceeds from note payable - Sponsor	`ProceedsFromRelatedPartyDebt`	-	USD	Annual
Proceeds from note payable - Sponsor	`ProceedsFromRelatedPartyDebt`	-	USD	3 Qtrs
Redemptions of Class A common stock	`PaymentsForRepurchaseOfCommonStock`	-	USD	3 Qtrs
Redemptions of Class A common stock	`PaymentsForRepurchaseOfCommonStock`	-	USD	3 Qtrs
Sale of units in public offering	`ProceedsFromIssuanceInitialPublicOffering`	-	USD	3 Qtrs
Sale of units in public offering	`ProceedsFromIssuanceInitialPublicOffering`	-	USD	3 Qtrs
Sale of private placement units	`ProceedsFromIssuanceOfPrivatePlacement`	-	USD	3 Qtrs
Sale of private placement units	`ProceedsFromIssuanceOfPrivatePlacement`	-	USD	3 Qtrs
Payment of offering costs	`PaymentsOfStockIssuanceCosts`	-	USD	3 Qtrs
Payment of offering costs	`PaymentsOfStockIssuanceCosts`	-	USD	3 Qtrs
Repayment of note payable - Sponsor	`RepaymentsOfRelatedPartyDebt`	-	USD	3 Qtrs
Repayment of note payable - Sponsor	`RepaymentsOfRelatedPartyDebt`	-	USD	3 Qtrs
Proceeds from issuance of option	`ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans`	-	USD	3 Qtrs
Proceeds from issuance of option	`ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans`	$498.00K	USD	3 Qtrs
Proceeds from the issuance of notes payable	`ProceedsFromNotesPayable`	-	USD	3 Qtrs
Proceeds from the issuance of notes payable	`ProceedsFromNotesPayable`	$182.00K	USD	3 Qtrs
Proceeds from issuance of Class B common stock to Sponsor	`ProceedsFromIssuanceOfCommonStock`	-	USD	3 Qtrs
Proceeds from issuance of Class B common stock to Sponsor	`ProceedsFromIssuanceOfCommonStock`	$151.00K	USD	3 Qtrs
Proceeds from issuance of convertible notes payable, carried at fair value	`ProceedsFromIssuanceOfConvertibleNotesPayableCarriedAtFairValue`	$1.47M	USD	3 Qtrs
Proceeds from issuance of convertible notes payable, carried at fair value	`ProceedsFromIssuanceOfConvertibleNotesPayableCarriedAtFairValue`	$503.00K	USD	3 Qtrs
Proceeds from issuance of convertible promissory note payable, carried at cost	`ProceedsFromConvertibleDebt`	$813.00K	USD	3 Qtrs
Proceeds from issuance of convertible promissory note payable, carried at cost	`ProceedsFromConvertibleDebt`	-	USD	3 Qtrs
Interest paid on convertible promissory note, carried at cost	`InterestPaidOnConvertiblePromissoryNoteCarriedAtCost`	$81.00K	USD	3 Qtrs
Interest paid on convertible promissory note, carried at cost	`InterestPaidOnConvertiblePromissoryNoteCarriedAtCost`	-	USD	3 Qtrs
Proceeds from sale of equity securities	`ProceedsFromSaleOfEquitySecurities`	-	USD	3 Qtrs
Proceeds from sale of equity securities	`ProceedsFromSaleOfEquitySecurities`	$1.34M	USD	Annual
Proceeds from sale of equity securities	`ProceedsFromSaleOfEquitySecurities`	$1.21M	USD	Annual
Proceeds from sale of equity securities	`ProceedsFromSaleOfEquitySecurities`	$830.00K	USD	3 Qtrs
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$1.90M	USD	Annual
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$1.51M	USD	3 Qtrs
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$11.34M	USD	3 Qtrs
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$2.45M	USD	Annual
Net change in cash and cash equivalents before effect of exchange rate changes	`NetChangeInCashAndCashEquivalentsBeforeEffectOfExchangeRates`	$-1.00K	USD	Annual
Net change in cash and cash equivalents before effect of exchange rate changes	`NetChangeInCashAndCashEquivalentsBeforeEffectOfExchangeRates`	-	USD	3 Qtrs
Net change in cash and cash equivalents before effect of exchange rate changes	`NetChangeInCashAndCashEquivalentsBeforeEffectOfExchangeRates`	$8.65M	USD	3 Qtrs
Net change in cash and cash equivalents before effect of exchange rate changes	`NetChangeInCashAndCashEquivalentsBeforeEffectOfExchangeRates`	$-253.00K	USD	Annual
Effect of exchange rate changes on cash and cash equivalents	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect`	-	USD	3 Qtrs
Effect of exchange rate changes on cash and cash equivalents	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect`	$1.00K	USD	Annual
Effect of exchange rate changes on cash and cash equivalents	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect`	$1.00K	USD	Annual
Effect of exchange rate changes on cash and cash equivalents	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect`	$-5.00K	USD	3 Qtrs
Net change in cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	-	USD	3 Qtrs
Net change in cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$-252.00K	USD	Annual
Net change in cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	-	USD	Annual
Net change in cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$8.64M	USD	3 Qtrs
Cash at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$252.00K	USD	Point-in-time
Cash at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	-	USD	Point-in-time
Cash at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	-	USD	Point-in-time
Cash at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	-	USD	Point-in-time
Cash at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$8.64M	USD	Point-in-time
Cash at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$8.64M	USD	Point-in-time
Cash at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	-	USD	Point-in-time
Cash at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	-	USD	Point-in-time
Cash at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	-	USD	Point-in-time
Cash at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$252.00K	USD	Point-in-time
Issuance of Conduit Pharmaceuticals Inc. common stock to Cizzle Biotechnology Holding PLC upon exercise of option	`IssuanceOfConduitPharmaceuticalsInc.CommonStockToCizzleBiotechnologyHoldingPlc`	$151.00K	USD	3 Qtrs
Issuance of Conduit Pharmaceuticals Inc. common stock to Cizzle Biotechnology Holding PLC upon exercise of option	`IssuanceOfConduitPharmaceuticalsInc.CommonStockToCizzleBiotechnologyHoldingPlc`	-	USD	3 Qtrs
Exchange of Conduit Pharmaceuticals Limited convertible notes for shares of Conduit Pharmaceuticals Inc. common stock in connection with the Merger	`ExchangeOfConduitPharmaceuticalsLimitedConvertibleNotesForSharesOfConduitPharmaceuticalsInc.CommonStockInConnectionWithMerger`	-	USD	3 Qtrs
Exchange of Conduit Pharmaceuticals Limited convertible notes for shares of Conduit Pharmaceuticals Inc. common stock in connection with the Merger	`ExchangeOfConduitPharmaceuticalsLimitedConvertibleNotesForSharesOfConduitPharmaceuticalsInc.CommonStockInConnectionWithMerger`	$3.69M	USD	3 Qtrs
Accrued transaction costs	`AccruedTransactionCosts`	$5.74M	USD	3 Qtrs
Accrued transaction costs	`AccruedTransactionCosts`	-	USD	3 Qtrs
Non-cash directors and officers insurance	`NoncashDirectorsAndOfficersInsurance`	-	USD	3 Qtrs
Non-cash directors and officers insurance	`NoncashDirectorsAndOfficersInsurance`	$1.07M	USD	3 Qtrs
FV of shares received related to the sale of future revenue	`FvOfSharesReceivedAndReceivableRelatedToSaleOfFutureRevenue`	$1.29M	USD	Annual
FV of shares received related to the sale of future revenue	`FvOfSharesReceivedAndReceivableRelatedToSaleOfFutureRevenue`	$1.47M	USD	Annual
Net Liabilities assumed in the Merger	`NoncashMergerFinancing`	$6.12M	USD	3 Qtrs
Net Liabilities assumed in the Merger	`NoncashMergerFinancing`	-	USD	3 Qtrs
Deferred commission payable	`DeferredUnderwritingCommissionPayable`	-	USD	3 Qtrs
Deferred commission payable	`DeferredUnderwritingCommissionPayable`	-	USD	3 Qtrs
Accrued excise tax on January 24, 2023 redemptions	`AccruedExciseTaxOnRedemptions`	-	USD	3 Qtrs
Accrued excise tax on January 24, 2023 redemptions	`AccruedExciseTaxOnRedemptions`	-	USD	3 Qtrs
Remeasurement of Class A common stock subject to possible redemption	`RemeasurementOfClassACommonStockSubjectToPossibleRedemption`	-	USD	3 Qtrs
Remeasurement of Class A common stock subject to possible redemption	`RemeasurementOfClassACommonStockSubjectToPossibleRedemption`	-	USD	3 Qtrs
Deferred offering costs included in accrued offering costs	`DeferredOfferingCostsIncludedInAccruedOfferingCosts`	-	USD	3 Qtrs
Deferred offering costs included in accrued offering costs	`DeferredOfferingCostsIncludedInAccruedOfferingCosts`	-	USD	3 Qtrs
Prepaid expenses paid by note payable - Sponsor	`PrepaidExpensesPaidByNotePayable`	-	USD	3 Qtrs
Prepaid expenses paid by note payable - Sponsor	`PrepaidExpensesPaidByNotePayable`	-	USD	3 Qtrs
Deferred offering costs paid by note payable - Sponsor	`DeferredOfferingCostsPaidByNotePayable`	-	USD	3 Qtrs
Deferred offering costs paid by note payable - Sponsor	`DeferredOfferingCostsPaidByNotePayable`	-	USD	3 Qtrs
Class A shares subject to redemption	`ClassASharesSubjectToRedemption`	-	USD	3 Qtrs
Class A shares subject to redemption	`ClassASharesSubjectToRedemption`	-	USD	3 Qtrs
Initial value of warrant liabilities issued in connection with PIPE Financing and Closing of the Merger	`InitialValueOfWarrantLiabilitiesIssuedInConnectionWithPipeFinancingAndClosingOfMerger`	$223.00K	USD	3 Qtrs
Initial value of warrant liabilities issued in connection with PIPE Financing and Closing of the Merger	`InitialValueOfWarrantLiabilitiesIssuedInConnectionWithPipeFinancingAndClosingOfMerger`	-	USD	3 Qtrs
Fair value of shares received and receivable related to the sale of future revenue	`FairValueOfSharesReceivedAndReceivableRelatedToSaleOfFutureRevenue`	-	USD	3 Qtrs
Fair value of shares received and receivable related to the sale of future revenue	`FairValueOfSharesReceivedAndReceivableRelatedToSaleOfFutureRevenue`	$1.28M	USD	3 Qtrs

Stockholders Equity 69 line items

Line Item	Tag	Value	Unit	Period
Beginning balance, value	`StockholdersEquity`	$-6.49M	USD	Point-in-time
Beginning balance, value	`StockholdersEquity`	$-10.09M	USD	Point-in-time
Beginning balance, value	`StockholdersEquity`	$-2.36M	USD	Point-in-time
Beginning balance, value	`StockholdersEquity`	$-1.08M	USD	Point-in-time
Beginning balance, value	`StockholdersEquity`	$-15.04M	USD	Point-in-time
Beginning balance, value	`StockholdersEquity`	$-6.14M	USD	Point-in-time
Beginning balance, value	`StockholdersEquity`	$-5.94M	USD	Point-in-time
Adjusted Balances, beginning of period	`StockholdersEquityAdjusted`	$-6.14M	USD	Point-in-time
Adjusted Balances, beginning of period	`StockholdersEquityAdjusted`	$-15.04M	USD	Point-in-time
Adjusted Balances, beginning of period	`StockholdersEquityAdjusted`	$-5.94M	USD	Point-in-time
Adjusted Balances, beginning of period	`StockholdersEquityAdjusted`	$-10.09M	USD	Point-in-time
Retroactive application of Merger	`StockholdersEquityRetroactiveApplicationOfMerger`	-	USD	3 Qtrs
Retroactive application of Merger	`StockholdersEquityRetroactiveApplicationOfMerger`	-	USD	1 Quarter
Retroactive application of Merger	`StockholdersEquityRetroactiveApplicationOfMerger`	-	USD	3 Qtrs
Retroactive application of Merger	`StockholdersEquityRetroactiveApplicationOfMerger`	-	USD	1 Quarter
Reclassification of additional paid-in-capital	`AdjustmentsToAdditionalPaidInCapitalOther`	-	USD	1 Quarter
Reclassification of additional paid-in-capital	`AdjustmentsToAdditionalPaidInCapitalOther`	-	USD	1 Quarter
Reclassification of additional paid-in-capital	`AdjustmentsToAdditionalPaidInCapitalOther`	-	USD	3 Qtrs
Reclassification of additional paid-in-capital	`AdjustmentsToAdditionalPaidInCapitalOther`	-	USD	3 Qtrs
Foreign currency translation adjustment	`OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent`	$36.00K	USD	3 Qtrs
Foreign currency translation adjustment	`OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent`	$79.00K	USD	Annual
Foreign currency translation adjustment	`OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent`	$608.00K	USD	1 Quarter
Foreign currency translation adjustment	`OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent`	$753.00K	USD	Annual
Foreign currency translation adjustment	`OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent`	$610.00K	USD	1 Quarter
Foreign currency translation adjustment	`OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent`	$1.27M	USD	3 Qtrs
Net income (loss)	`NetIncomeLoss`	$-1.82M	USD	3 Qtrs
Net income (loss)	`NetIncomeLoss`	$-4.89M	USD	Annual
Net income (loss)	`NetIncomeLoss`	$-956.00K	USD	1 Quarter
Net income (loss)	`NetIncomeLoss`	$-3.66M	USD	Annual
Net income (loss)	`NetIncomeLoss`	$1.99M	USD	1 Quarter
Net income (loss)	`NetIncomeLoss`	$-2.31M	USD	3 Qtrs
Reclassification of additional paid-in capital**	`AdjustmentsToAdditionalPaidInCapitalOther`	-	USD	1 Quarter
Reclassification of additional paid-in capital**	`AdjustmentsToAdditionalPaidInCapitalOther`	-	USD	1 Quarter
Reclassification of additional paid-in capital**	`AdjustmentsToAdditionalPaidInCapitalOther`	-	USD	3 Qtrs
Reclassification of additional paid-in capital**	`AdjustmentsToAdditionalPaidInCapitalOther`	-	USD	3 Qtrs
Issuance of Conduit Pharmaceuticals Inc. common stock to holders of Conduit Pharmaceuticals Limited convertible notes on the Closing Date (Note 3)	`StockIssuedDuringPeriodValueConversionOfConvertibleSecurities`	$3.69M	USD	1 Quarter
Issuance of Conduit Pharmaceuticals Inc. common stock to holders of Conduit Pharmaceuticals Limited convertible notes on the Closing Date (Note 3)	`StockIssuedDuringPeriodValueConversionOfConvertibleSecurities`	$3.69M	USD	3 Qtrs
Issuance of Conduit Pharmaceuticals Inc. common stock to holders of Conduit Pharmaceuticals Limited convertible notes on the Closing Date, shares	`StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities`	373,570.00	shares	3 Qtrs
Merger, net of redemptions (Note 3)	`StockIssuedDuringPeriodValueAcquisitions`	$13.56M	USD	1 Quarter
Merger, net of redemptions (Note 3)	`StockIssuedDuringPeriodValueAcquisitions`	$13.56M	USD	3 Qtrs
Sale of Private Placement Units, net of offering costs	`StockIssuedDuringPeriodValueNewIssues`	$19.78M	USD	1 Quarter
Sale of Private Placement Units, net of offering costs	`StockIssuedDuringPeriodValueNewIssues`	$3.90M	USD	Point-in-time
Sale of Private Placement Units, net of offering costs	`StockIssuedDuringPeriodValueNewIssues`	3.25M	GBP	Point-in-time
Sale of Private Placement Units, net of offering costs	`StockIssuedDuringPeriodValueNewIssues`	$19.78M	USD	3 Qtrs
Issuance of Conduit Pharmaceuticals Inc. common stock to Cizzle Biotechnology Holding PLC	`StockIssuedDuringPeriodValuePurchaseOfRevenue`	$151.00K	USD	1 Quarter
Issuance of Conduit Pharmaceuticals Inc. common stock to Cizzle Biotechnology Holding PLC	`StockIssuedDuringPeriodValuePurchaseOfRevenue`	$151.00K	USD	3 Qtrs
Issuance of Conduit Pharmaceuticals Inc. common stock to an advisor for services directly related to the Merger (Note 3)	`StockIssuedDuringPeriodValueIssuedForServices`	-	USD	1 Quarter
Issuance of Conduit Pharmaceuticals Inc. common stock to an advisor for services directly related to the Merger (Note 3)	`StockIssuedDuringPeriodValueIssuedForServices`	-	USD	3 Qtrs
Reduction of excise tax liability associated with the Merger (Note 3)	`AdjustmentsToAdditionalPaidInCapitalReductionOfExciseTaxLiabilityAssociatedWithMerger`	$1.14M	USD	3 Qtrs
Reduction of excise tax liability associated with the Merger (Note 3)	`AdjustmentsToAdditionalPaidInCapitalReductionOfExciseTaxLiabilityAssociatedWithMerger`	$1.14M	USD	1 Quarter
Capital contribution - related party	`AdjustmentsToAdditionalPaidInCapitalContributionRelatedParty`	$150.00K	USD	1 Quarter
Capital contribution - related party	`AdjustmentsToAdditionalPaidInCapitalContributionRelatedParty`	$150.00K	USD	3 Qtrs
Stock-based compensation	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$10.00K	USD	3 Qtrs
Stock-based compensation	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$10.00K	USD	1 Quarter
Reclassification of additional paid-in-capital	`ReclassificationOfAdditionalPaidincapitalBeforeAdjusted`	-	USD	3 Qtrs
Foreign currency translation adjustment	`OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent`	$610.00K	USD	1 Quarter
Foreign currency translation adjustment	`OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent`	$753.00K	USD	Annual
Foreign currency translation adjustment	`OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent`	$1.27M	USD	3 Qtrs
Foreign currency translation adjustment	`OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent`	$79.00K	USD	Annual
Foreign currency translation adjustment	`OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent`	$36.00K	USD	3 Qtrs
Foreign currency translation adjustment	`OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent`	$608.00K	USD	1 Quarter
Foreign currency translation adjustment	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$79.00K	USD	Annual
Ending balance, value	`StockholdersEquity`	$-6.14M	USD	Point-in-time
Ending balance, value	`StockholdersEquity`	$-6.49M	USD	Point-in-time
Ending balance, value	`StockholdersEquity`	$-10.09M	USD	Point-in-time
Ending balance, value	`StockholdersEquity`	$-2.36M	USD	Point-in-time
Ending balance, value	`StockholdersEquity`	$-1.08M	USD	Point-in-time
Ending balance, value	`StockholdersEquity`	$-15.04M	USD	Point-in-time
Ending balance, value	`StockholdersEquity`	$-5.94M	USD	Point-in-time

Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.